Elevance Health Files 8-K for Regulation FD Disclosure

TL;DR

ELEVANCE HEALTH (ELV) FILED AN 8-K FOR REG FD DISCLOSURE - NO NEW INFO YET

AI Summary

Elevance Health, Inc. filed an 8-K on May 28, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the disclosure itself.

Why It Matters

This filing indicates Elevance Health is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

• Elevance Health, Inc. (company) — Registrant
• Regulation FD (regulation) — Disclosure type
• May 28, 2025 (date) — Filing date
• Anthem, Inc. (company) — Former company name
• WELLPOINT, INC (company) — Former company name

FAQ

From the Filing

0001156039-25-000096.txt : 20250528 0001156039-25-000096.hdr.sgml : 20250528 20250528063133 ACCESSION NUMBER: 0001156039-25-000096 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250528 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance EIN: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 25991094 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 elv-20250528.htm 8-K elv-20250528 FALSE 0001156039 0001156039 2025-05-28 2025-05-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2025 Date of Report (Date of earliest event reported) ___________________________________ Elevance Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission File Number) 35-2145715 (I.R.S. Employer Identification Number) 220 Virginia Ave Indianapolis , IN 46204 (Address of principal executive offices and zip code) ( 833 ) 401-1577 (Registrant's telephone number, including area code) ________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.01 ELV NYSE Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 - Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) expect to speak with investors this week. During these meetings, Company officers expect to reaffirm the Company’s shareholders’ earnings guidance for full year 2025 to be $28.30 to $29.00 per diluted share, including approximately $5.85 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders’ earnings to be $34.15 to $34.85 per diluted share. This does not include any other adjustment items beyond those reported in the Company's first quarter 2025 earnings. During these meetings, Company officers are a